Evidence summary
What the cited records say
FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.↗↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
Cited context
Related records
Organizations named in cited records
- U.S. Food and Drug Administration↗
Dated source history
Updates connected to this profile
No dated update is published for this profile. PeptideScanner does not monitor every source continuously; the current profile summary and cited records remain available below.